Introduction
============

Idiopathic membranous nephropathy (IMN) is an organ-specific autoimmune inflammatory disease of the kidneys ([@b1-etm-0-0-8506]). IMN is the primary glomerular disease affecting adults \>60 years of age and is a common cause of adult-onset nephropathy syndrome (NS) ([@b1-etm-0-0-8506]). IMN is characterized by thickening of the basement membrane ([@b4-etm-0-0-8506]) with subepithelial deposits of immune complexes mostly composed of immunoglobulin (Ig)G and the complement protein C3 ([@b5-etm-0-0-8506],[@b6-etm-0-0-8506]), which are detectable using immunofluorescence or electron microscopy. Clinical presentations of IMN vary from subnephropathy range proteinuria to NS with heavy proteinuria, also including hypertension, renal insufficiency and microscopic hematuria ([@b7-etm-0-0-8506]). Previous studies of the natural history of IMN have reported that 5-30 and 40% of patients with IMN have spontaneous complete or partial remission after 5 years, respectively, whereas IMN in 30-40% of patients progresses to end-stage renal disease (ESRD) within 5-15 years ([@b8-etm-0-0-8506],[@b9-etm-0-0-8506]). Among hospitalized patients with primary glomerular nephropathy, a decreasing trend in IgA nephropathy and an increasing trend of IMN were reported by some researchers ([@b10-etm-0-0-8506]). Globally, hypertension acts as one of the leading etiologies for chronic kidney disease (CKD) ([@b11-etm-0-0-8506]). Moreover, as some patients have CKD due to high blood pressure, hypertension is considered secondary to renal diseases ([@b12-etm-0-0-8506]). A previous study reported that high blood pressure during renal biopsy is a poor prognostic factor of patients with IMN ([@b13-etm-0-0-8506]). The association between IMN and hypertension is not fully understood up to now. The present study hypothesized that hypertension worsens IMN prognosis and serves a central role in IMN disease progression. The present study investigated whether hypertension was associated with clinical parameters in IMN and examined IMN prognosis. Therefore, these clinicians can monitor and treat patients with PMN who may be inclined to hypertension, as to reduce occurrence of patients with PMN with hypertension and delay disease progression.

Materials and methods
=====================

### Study population

The present retrospective study recruited patients with IMN from The First Affiliated Hospital of Nanchang University (Nanchang, China) between January 2010 and June 2018. NS was defined according to the standard criteria used in Japan ([@b14-etm-0-0-8506]): i) Urine protein excretion (3.5 g/day); ii) serum albumin (3.0 g/dl) or serum total protein (6.0 g/dl); iii) presence of edema; and iv) total cholesterol (250 mg/dl). The first and second criteria are considered necessary to diagnose IMN ([@b15-etm-0-0-8506]). According to the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis, IMN can be diagnosed by kidney biopsy ([@b16-etm-0-0-8506]). Patients with systemic diseases, such as rheumatic diseases, malignant tumors, hepatitis B or C virus infection, tuberculosis and other kidney diseases were excluded from the study ([@b17-etm-0-0-8506]). Patients \<18 years old were also excluded. A total of 220 patients (male, 137; female, 83; age, 18-75 years; mean age 51.21±12.78 years) with previously diagnosed IMN were included in the study. The inclusion criteria were as follows: i) Age, 18-75 years; ii) MN diagnosed by renal biopsy; iii) informed consent form signed voluntarily by the participant; and iv) antihypertensive drugs were administered, but no statins or other drugs were received. The exclusion criteria were as follows: i) Patients with infections, malignant tumors, tuberculosis or other serious kidney diseases; ii) patients with insufficient follow-up; and iii) patients determined to be inappropriate for participation in the study by an investigator. The study was reviewed and approved by The Ethics Committee of The Nanchang University Hospital. All patients signed a patient consent form.

### Study design

The enrolled patients were divided into two groups based on the criteria for hypertension: Hypertension and non-hypertension groups. Hypertension was defined as average systolic blood pressure (SBP) ≥140 mmHg or average diastolic blood pressure (DBP) ≥90 mmHg ([@b21-etm-0-0-8506]). Patients with a history of hypertension whose BP was not above the mentioned level following hospitalization with antihypertensive drugs were also classified under the hypertension group. BP was measured by an experienced physician using a mercury sphygmomanometer and an appropriately sized cuff applied to the right arm at heart level after ≥5 min of rest in a seated position. The present study examined 100 patients with IMN and hypertension (hypertension group) and 120 patients with IMN without hypertension (non-hypertension group) who underwent renal biopsy at The First Affiliated Hospital of Nanchang University.

### Clinical parameters

Basic demographic data included age, sex, course of the disease, edema, hypertension history, SBP, DBP and mean arterial pressure (MAP). The present study measured red blood cell count (RBC), hemoglobin (Hb), total protein (TP), albumin, serum creatinine (Scr), uric acid (UA), potassium (K), calcium (Ca), phosphorus (P), triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and calculated estimated glomerular filtration rate (e-GFR) were collected from 220 patients with IMN.The e-GFR was calculated using the CKD-EPI creatinine equation recommended by the KDIGO and was expressed as ml/min/1.73 m^2^ of body surface area ([@b22-etm-0-0-8506]). In addition, 24 h urine protein was measured.

### Histopathologic parameters

The kidney biopsy specimens frozen as 5 µm sections, dried at room temperature for 30 min, fixed using acetone at 4˚C for 10 min and washed three times using PBS. Fluorescein labeled antibody \[Rabbit Anti Human IgG/FITC; cat. no. GF020229; 1:80; Rabbit Anti Human IgA/FITC; cat. no. GF020429; 1:40; Rabbit Anti Human IgM/FITC cat. no. GF020329; 1:40; Rabbit Anti Human Fibrinogen/FITC; cat. no. GF011129; 1:40; Rabbit Anti Human C1q Complement/FITC; cat. no. GF025429; 1:40; Rabbit Anti Human C3c Complement/FITC; cat. no. GF020129; 1:20; all, Gene Tech (Shanghai) Co., Ltd.\] was used and incubate with 37˚C for 30 min. Tissues were watched with PBS three times and sealed using glycerin. Tissues were then observed using fluorescence microscope (magnification, x100; eyepiece, magnification, x10; objective magnification, x10). Renal biopsy specimens including ≥10 glomeruli were analyzed. All renal biopsies were processed according to the standard techniques of light microscopy (magnification, x400), immunofluorescence microscopy (magnification, x400) and electron microscopy (magnification, x2,000) ([@b7-etm-0-0-8506]). To confirm the pathology, all samples were reviewed by two pathologists in The First Affiliated Hospital of Nanchang University. The following parameters were assessed by histopathology: Glomerular sclerosis, segmental sclerosis, ischemic sclerosis, crescents, mesangial cells and matrix hyperplasia. In addition, mesangial hypercellularity, interstitial fibrosis, tubular atrophy and vascular lesions were measured. These parameters was analyzed using SPSS software (version 22.0; IBM Corp.).

### End-point of the study

Disease progression was defined as a ≥50% decline in the baseline e-GFR, doubling of Scr levels, diagnosis of ESRD and requiring renal replacement therapy after follow-up ([@b23-etm-0-0-8506]), including hemodialysis, peritoneal dialysis and kidney transplant, and death. The present study reviewed the medical record of each patient retrospectively from the date of renal biopsy to death, the development of ESRD or the last clinical visit (November 15, 2018). The average follow-up was 35.70 months.

### Statistical analysis

Statistical analysis was performed using SPSS software (version 22.0; IBM Corp.). Continuous data are presented as the mean ± SD, whereas categorical data are presented as frequencies and percentages. Differences in continuous variables between the two groups were assessed using independent t-tests. A comparison of univariate predictors of clinical outcomes between the groups was performed using χ^2^ test for categorical variables. The renal progression-free rates were calculated using the Kaplan-Meier analysis and comparisons between the groups were performed using the log-rank test. Multivariate Cox proportional hazard regression analysis was performed to determine independent variables associated with the renal outcomes. The results are presented as hazard ratio (H) with a 95% CI. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Comparison of demographic and laboratory parameters between the two groups

IMN is known to be a common cause of primary glomerulopathy ([@b10-etm-0-0-8506]). The present study examined 100 patients with IMN associated with hypertension (hypertension group) and 120 patients with IMN without hypertension (non-hypertension group) that underwent renal biopsy at The First Affiliated Hospital of Nanchang University. In the present study, the prevalence of hypertension was 45.45% among the patients. Baseline characteristics of patients with and without hypertension are summarized in [Table I](#tI-etm-0-0-8506){ref-type="table"}. Among the patients, 137 (62.2%) were male and 83 (37.7%) were female, with a male to female ratio of 1.65:1. The mean age of patients with IMN was 51.21±12.78 years. A significant difference was found in the age (P=0.001), hypertension history (P\<0.0001), SBP (P\<0.0001), DBP (P\<0.0001), MAP (P\<0.0001), albumin (P=0.046), Scr (P=0.001), LDL (P=0.018), 24 h urine protein (P=0.028) and e-GFR (P=0.013) between the groups with and without hypertension. There were no significant differences in the following parameters between the two groups: Sex, course of the disease, edema, RBC, Hb, TP, UA, K, Ca, P, TG, TC and HDL.

### Comparison of pathological parameters between the two groups

Analysis of pathological parameters between the hypertension and non-hypertension groups is shown in [Table II](#tII-etm-0-0-8506){ref-type="table"}. Ischemic sclerosis and vascular lesions were associated with hypertension in IMN. The present univariate analysis results suggested that glomerular sclerosis, segmental sclerosis, ischemic sclerosis, interstitial fibrosis, tubular atrophy and vascular lesions were associated with the primary outcome in patients with IMN and hypertension.

### Survival analysis of cumulative renal survival rate of hypertension and non-hypertension groups, and risk factors associated with patients with IMN and hypertension developing into ESRD

Follow-up data were available for 220 patients with IMN with and without hypertension. Average observation time was 35.70 months (range, 5.10-103.77 months). In total, 54 patients reported a 50% decline in e-GFR or doubling of Scr levels. During follow-up, in eight patients IMN had progressed to ESRD. There were nine cases of mortality and the cause of death was unknown. The renal survival rates in patients with hypertension were significantly reduced compared with patients without hypertension (log-rank test, P=0.034; [Fig. 1](#f1-etm-0-0-8506){ref-type="fig"}). The present Cox proportional hazard regression results suggested that DBP may be an independent risk factor for IMN progression (H, 5.160; CI, 0.865-0.989; P=0.023). The present results suggested that age (H, 4.839; CI, 1.008-1.142; P=0.028), sex (H, 5.680; CI, 0.031-0.714; P=0.017), Scr (H, 20.920; CI, 1.035-1.089; P\<0.001), UA (H, 4.783; CI, 0.982-0.0.999; P=0.029), 24 h urine protein (H, 6.318; CI, 1.079-0.1.850; P=0.012) and e-GFR (H, 4.008; CI, 1.001-1.062; P=0.045) were significant and independent risk factors in patients with IMN with hypertension. Glomerular sclerosis (H, 8.722; CI, 1.860-21.559; P=0.003), segmental sclerosis (H, 7.737; CI, 7.770-13.219; P=0.005), percentage of ischemic sclerosis (H, 4.729; CI, 1.444-11.945; P=0.030), crescents (H, 5.938; CI, 0.003-0.526; P=0.015), interstitial fibrosis (H, 8.128; CI, 0.005-1.052; P=0.043), and vascular lesions (H, 4.049; CI, 1.030-9.766; P=0.044) were also identified as significant and independent risk factors in patients with IMN with hypertension ([Table III](#tIII-etm-0-0-8506){ref-type="table"}).

Discussion
==========

IMN is the most common primary glomerular disease in individuals \>60 years old ([@b24-etm-0-0-8506]). In patients with IMN, one-third of patients with spontaneous remission report progressive renal failure, whereas the remaining patients report stable renal function ([@b25-etm-0-0-8506]). Nephritic syndrome, massive proteinuria, hematuria, impaired renal function and hypertension are common in IMN ([@b26-etm-0-0-8506]). The results from previous studies on IMN prognostic factors are highly variable ([@b12-etm-0-0-8506]). In addition, whether demographic parameters, laboratory parameters and histological lesions contribute to the improvement of renal function in patients with hypertension is not fully understood.

The present retrospective study investigated the prognosis and risk factors for renal survival in patients with IMN with hypertension. In the present study, the majority of patients with IMN were \>40 years. A higher incidence of hypertension among elderly patients compared with adult patients has previously been reported ([@b27-etm-0-0-8506]). The present results are consistent with the results of the previous studies ([@b28-etm-0-0-8506],[@b29-etm-0-0-8506]). Moreover, the present study identified that Scr, LDL and 24 h urine protein were increased, and serum albumin and e-GFR were decreased in patients with IMN with hypertension. Huh *et al* ([@b18-etm-0-0-8506]) reported that low serum albumin levels at the onset of the disease were associated with poor renal prognosis of patients with IMN. Another previous study reported that high levels of Scr at diagnosis are major predictors of the progression of IMN to ESRD ([@b30-etm-0-0-8506]). Proteinuria has also been used as a major predictor for renal prognosis of IMN in a conventional predictive model ([@b31-etm-0-0-8506]). Patients with limited proteinuria are deemed to have a better prognosis ([@b31-etm-0-0-8506]). Previous studies identified lower e-GFR to be significantly associated with the risk of progression of IMN to ESRD ([@b32-etm-0-0-8506],[@b33-etm-0-0-8506]). The present results suggested that hypertension may be associated with the severity of IMN, which is consistent with results from previous studies. In the majority of studies, hypertension was not indicated to be an independent predictor of MN ([@b34-etm-0-0-8506],[@b35-etm-0-0-8506]). To the best of our knowledge, the present study was the first to identify primary factors for hypertension development in patients with IMN using a retrospective study design, measuring parameters such as uric acid, age and sex ([@b36-etm-0-0-8506]).

The mechanism of hypertension and disease severity, and whether hypertension can exacerbate kidney disease is not fully understood. The present results suggested that age and sex were statistically significant between the hypertension and non-hypertension groups, which were in line with findings from a previous study ([@b37-etm-0-0-8506]). Uric acid was previously reported to be independently associated with prevalent CKD and hypertension ([@b36-etm-0-0-8506],[@b38-etm-0-0-8506]). Hypertension can cause nephroangiosclerosis ([@b39-etm-0-0-8506]). The severity of renal histological lesions, particularly of interstitial fibrosis, glomerular sclerosis and vasculopathy, are considered negative prognostic indicators for IMN ([@b40-etm-0-0-8506]). The present results suggested that interstitial fibrosis, glomerular sclerosis, vasculopathy and crescents were significantly different between the hypertension and non-hypertension groups. However, other parameters were not statistically significant in the present study, which may be attributed to the small sample size. The present results suggested that the accumulated survival rate was significantly higher in patients with IMN without hypertension compared with patients with hypertension. In the present study, a multivariate Cox proportional hazards regression analysis was performed to investigate the association of DBP with renal outcomes. A previous study showed that patients with IMN suffered from CKD as a result of hypertension, and that hypertension was secondary to renal disease ([@b18-etm-0-0-8506]). Therefore, monitoring BP during diagnosis in patients with IMN may facilitate prognosis.

The present study had several limitations, such as a small number of patients with IMN, which limited the statistical power of the study. Therefore, future studies with larger sample sizes and longer periods of follow-up are required to investigate the influence of BP in patients with IMN. In addition, the present study did not analyze antibodies against phospholipase A2 receptors and thrombospondin type I domain-containing 7A, which have been suggested to be correlated with IMN disease severity ([@b41-etm-0-0-8506]). Finally, the primary outcome of MN can be complete and partial remission, including remission of proteinuria ([@b42-etm-0-0-8506]); however, in the present study, quantitative proteinuria was not followed up at the end-point of the study.

In conclusion, the present results suggested that patients with IMN with hypertension reported worse clinicopathological features and lower cumulative renal survival rate compared with patients without hypertension. The present results suggested that DBP may be an independent risk factor for the development of IMN with hypertension. Early detection and correction of hypertension could help delay the deterioration of renal function and improve prognosis of patients with IMN.
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###### 

Comparison of demographic and laboratory parameters between the two groups.

  Parameters             HG             NHG            T or χ^2^   P-value
  ---------------------- -------------- -------------- ----------- ----------
  Age, years             54.34±13.10    48.60±11.94    -3.4        0.001
  Sex                                                  0.04        0.839
       Male              63 (28.60)     74 (33.60)                  
       Female            37 (16.80)     46 (20.90)                  
  Course of disease      5.81±8.55      6.4±11.29      0.43        0.668
  Edema                                                0.82        0.499
       Yes               92 (41.80)     106 (48.20)                 
       No                8 (3.60)       14 (6.40)                   
  Hypertension history                                 48.26       P\<0.001
       Yes               34 (15.50)     0 (0.00)                    
       No                66 (30.00)     120 (54.50)                 
  SBP, mmHg              144.07±19.28   115.74±12.92   -12.54      P\<0.001
  DBP, mmHg              90.66±13.08    74.22±8.95     -10.66      P\<0.001
  MAP, mmHg              108.46±13.31   88.06±8.97     -13.05      P\<0.001
  RBCx10^12^/l           4.35±0.67      4.38±0.71      0.31        0.758
  Hb, g/l                129.19±22.21   128.35±19.35   -0.3        0.765
  TP, g/l                46.96±8.48     47.35±8.02     0.35        0.727
  Alb, g/l               23.50±6.75     25.20±6.01     2.01        0.046
  Scr, g/l               91.1±46.68     74.25±24.93    -3.25       0.001
  UA, µmol/l             371.56±78.67   367.34±93.28   -0.36       0.72
  K, mmol/l              4.00±0.54      4.01±0.45      0.23        0.818
  Ca, mmol/l             2.02±0.18      2.06±0.16      1.63        0.104
  P, mmol/l              1.18±0.19      1.14±0.22      -1.13       0.26
  TG, mmol/l             3.15±2.55      2.57±2.11      -1.85       0.065
  TC, mmol/l             7.25±2.01      6.78±1.91      -1.79       0.075
  HDL, mmol/l            1.48±0.59      1.59±0.68      1.3         0.196
  LDL, mmol/l            5.03±2.14      4.40±1.73      -2.38       0.018
  24 h UP g/24 h         4.56±2.52      3.83±2.35      -2.21       0.028
  e-GFR                  81.83±35.32    94.09±36.65    2.51        0.013

n=220. Data are presented as mean ± SD or percentages (in brackets). HG, hypertension group; NHG, non-hypertension group; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RBC, red blood cell count; Hb, hemoglobin; TP, total protein; Alb, albumin; Scr, serum creatinine; UA, uric acid; K, potassium; Ca, calcium; P, phosphate; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low-density lipoprotein; 24 h UP, 24 h urine protein; e-GFR, calculated estimated glomerular filtration rate.

###### 

Comparison of pathological parameters between the two groups.

  Parameter                     HG           NHG          T or χ^2^   P-value
  ----------------------------- ------------ ------------ ----------- ---------
  GS, case (%)                  31 (14.09)   33 (15.00)   0.778       0.036
  PGS (%)                       0.06±0.11    0.04±0.09    -1.32       0.188
  SS, case (%)                  3 (1.36)     4 (1.82)     -0.15       0.048
  PSS (%)                       0.004±0.02   0.004±0.02   -0.08       0.939
  IS, case (%)                  27 (12.27)   28 (12.73)   -0.822      0.011
  PIS (%)                       0.04±0.10    0.05±0.13    0.14        0.886
  Crescent, case (%)            8 (3.64)     7 (3.18)     -0.65       0.515
  Percentage of crescents (%)   0.02±0.08    0.004±0.02   -1.56       0.122
  MC/MAH                                                  2.351       0.314
       0                        15 (6.82)    19 (8.64)                 
       \<25%                    60 (27.27)   81 (36.82)                
       25-49%                   25 (11.36)   20 (9.09)                 
       50-74%                   0 (0.00)     0 (0.00)                  
       \>75%                    0 (0.00)     0 (0.00)                  
  MEH                                                     5.915       0.2
       0                        15 (6.82)    23 (10.45)                
       \<25%                    23 (10.45)   24 (10.91)                
       25-49%                   52 (23.64)   69 (31.36)                
       50-74%                   8 (3.64)     2 (0.91)                  
       \>75%                    2 (0.91)     2 (0.91)                  
  IF                                                      5.399       0.038
       0                        61 (27.73)   76 (34.55)                
       \<25%                    7 (3.18)     6 (2.73)                  
       25-49%                   26 (11.82)   36 (16.36)                
       50-74%                   4 (1.82)     0 (0.00)                  
       \>75%                    2 (0.91)     2 (0.91)                  
  TA                                                      9.449       0.041
       0                        18 (8.18)    25 (11.36)                
       \<25%                    20 (9.09)    29 (13.18)                
       25-49%                   53 (24.09)   64 (29.09)                
       50-74%                   7 (3.18)     0 (0.00)                  
       \>75%                    2 (0.91)     2 (0.91)                  
  VL                                                      1.107       0.023
       Yes                      74 (33.64)   81 (36.82)                
       No                       26 (11.82)   39 (17.73)                

n=220. Data are presented as mean ± SD or percentages (in brackets). HG, hypertension group; NHG, non-hypertension group; GS, glomerular sclerosis; PGS, percentage of GS; SS, segmental sclerosis; PSS, percentage of SS; IS, is chemic sclerosis; PIS, percentage of IS; MC/MAH, mesangial cell and matrix hyperplasia; MEH, mesangial hypercellularity; IF, interstitial fibrosis; TA, tubular atrophy; VL, vascular lesion.

###### 

Multivariate Cox hazard regression analysis of the disease risk factors and patients with idiopathic membranous nephropathy with hypertension developing into end-stage renal disease.

                                                                         95.0% CI   
  ----------------------- -------- ------- -------- --------- ---------- ---------- --------
  Age, years              0.070    0.032   4.839    0.028     1.073      1.008      1.142
  Sex                     -1.899   0.797   5.680    0.017     0.150      0.031      0.714
  DBP, mmHg               -0.078   0.034   5.160    0.023     0.925      0.865      0.989
  Scr, µmol/l             0.060    0.013   20.920   \<0.001   1.062      1.035      1.089
  UA, µmol/l              -0.010   0.004   4.783    0.029     0.990      0.982      0.999
  24 h urine protein, g   0.346    0.138   6.318    0.012     1.413      1.079      1.850
  e-GFR                   0.030    0.015   4.008    0.045     1.031      1.001      1.062
  Glomerular sclerosis    1.846    0.625   8.722    0.003     6.333      1.860      21.559
  Segmental sclerosis     6.942    2.496   7.737    0.005     1034.718   7.770      13.219
  Percentage of IS        3.722    1.711   4.729    0.030     41.328     1.444      11.945
  Crescents               -3.286   1.348   5.938    0.015     0.037      0.003      0.526
  Interstitial fibrosis   0.010    0.013   8.128    0.043     1.023      0.005      1.052
  Vascular lesion         1.154    0.574   4.049    0.044     3.172      1.030      9.766

DBP, diastolic blood pressure; Scr, serum creatinine; UA, uric acid; e-GFR, calculated estimated glomerular filtration rate; IS ischemic sclerosis; B, regression coefficient; SE, standard error.
